Literature DB >> 29239621

A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.

Rachel Vickers Smith1, Elaine M Boland1, April M Young1, Michelle R Lofwall1, Alexa Quiroz1, Michele Staton1, Jennifer R Havens1.   

Abstract

Gabapentin, an anticonvulsant and analgesic for postherpetic neuralgia, has been thought to have no abuse potential despite numerous published reports to the contrary. Gabapentin has been linked with impaired driving and opioid use, highlighting the need to more fully understand its risk profile. Thirty-three individuals reporting recent nonmedical use of gabapentin were recruited from two ongoing longitudinal studies of drug users in Appalachian Kentucky to participate in focus groups. Four sessions were held (two in the community and two in jail settings), during which participants responded to questions regarding their personal experiences with gabapentin misuse. Focus group participants were similar to other gabapentin users in the larger cohort studies with respect to demographics and drug use behaviors. Overall, the sample reported having initiated gabapentin more than 10 years earlier after having it prescribed for a legitimate, though generally off-label, medical indication (e.g., pain, anxiety, opioid detoxification). Participants reported use of gabapentin in combination with buprenorphine, other opioids, cocaine, and caffeine to produce sought-after central nervous system effects (e.g., muscle relaxation, pain reduction, sleep induction, feeling drunk, and feeling "high"). Focus group responses highlighted the low cost of gabapentin for the purpose of getting high and noted increasing popularity in the community, particularly over the last 2 years. Gabapentin was a prominent drug of abuse in two cohorts of the primarily opioid-using individuals. Providers should be aware of gabapentin's abuse potential, and a reexamination of the need for scheduling is warranted. (PsycINFO Database Record (c) 2018 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29239621      PMCID: PMC5805633          DOI: 10.1037/adb0000337

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  24 in total

1.  Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data.

Authors:  Fabrizio Schifano; Stefano D'Offizi; Michele Piccione; Ornella Corazza; Paolo Deluca; Zoe Davey; Giuditta Di Melchiorre; Lucia Di Furia; Magí Farré; Liv Flesland; Miia Mannonen; Aino Majava; Stefania Pagani; Teuvo Peltoniemi; Holger Siemann; Arvid Skutle; Marta Torrens; Cinzia Pezzolesi; Peer van der Kreeft; Norbert Scherbaum
Journal:  Psychother Psychosom       Date:  2011-01-04       Impact factor: 17.659

2.  Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky.

Authors:  Rachel V Smith; Michelle R Lofwall; Jennifer R Havens
Journal:  Am J Psychiatry       Date:  2015-05       Impact factor: 18.112

3.  Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK.

Authors:  Vikas Kapil; Jody L Green; Marie-Claire Le Lait; David M Wood; Paul I Dargan
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

4.  Potentiation of the effect of buprenorphine/naloxone with gabapentin or quetiapine.

Authors:  Roy R Reeves; Mark E Ladner
Journal:  Am J Psychiatry       Date:  2014-06       Impact factor: 18.112

Review 5.  Gabapentin: Abuse, Dependence, and Withdrawal.

Authors:  Tracey L Mersfelder; William H Nichols
Journal:  Ann Pharmacother       Date:  2015-12-31       Impact factor: 3.154

6.  An exploratory study of mental health and HIV risk behavior among drug-using rural women in jail.

Authors:  Michele Staton-Tindall; Kathi L H Harp; Alexandra Minieri; Carrie Oser; J Matthew Webster; Jennifer Havens; Carl Leukefeld
Journal:  Psychiatr Rehabil J       Date:  2015-03

7.  Gabapentin-induced delirium and dependence.

Authors:  Stefan P Kruszewski; Richard P Paczynski; David A Kahn
Journal:  J Psychiatr Pract       Date:  2009-07       Impact factor: 1.325

8.  Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers.

Authors:  Colin R W Baird; Pauline Fox; Lesley A Colvin
Journal:  Eur Addict Res       Date:  2013-10-31       Impact factor: 3.015

9.  Prevalence of gabapentin in impaired driving cases in Washington State in 2003-2007.

Authors:  Brianna L Peterson
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

10.  Clinical outcomes in newer anticonvulsant overdose: a poison center observational study.

Authors:  Brandon Wills; Penny Reynolds; Eileen Chu; Christine Murphy; Kirk Cumpston; Paul Stromberg; Rutherfoord Rose
Journal:  J Med Toxicol       Date:  2014-09
View more
  10 in total

1.  Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers.

Authors:  Mance E Buttram; Steven P Kurtz; Matthew S Ellis; Theodore J Cicero
Journal:  J Subst Abuse Treat       Date:  2019-07-21

2.  Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system.

Authors:  Rachel Vickers-Smith; Jiangwen Sun; Richard J Charnigo; Michelle R Lofwall; Sharon L Walsh; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2019-11-02       Impact factor: 4.492

3.  An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user.

Authors:  Mance E Buttram; Steven P Kurtz; Theodore J Cicero; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2019-09-13       Impact factor: 4.492

4.  Factors Associated with Gabapentin Misuse among People Who Inject Drugs in Appalachian Kentucky.

Authors:  Mance E Buttram; Hilary L Surratt
Journal:  Subst Use Misuse       Date:  2020-09-11       Impact factor: 2.164

5.  A Qualitative Examination of Gabapentin Misuse Inside of Treatment and Recovery Settings.

Authors:  Mance E Buttram; Steven P Kurtz
Journal:  J Stud Alcohol Drugs       Date:  2020-09       Impact factor: 2.582

6.  Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016.

Authors:  Nathan J Pauly; Chris Delcher; Svetla Slavova; Eric Lindahl; Jeff Talbert; Patricia R Freeman
Journal:  J Manag Care Spec Pharm       Date:  2020-03

7.  Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions.

Authors:  Mohamed Elsayed; René Zeiss; Maximilian Gahr; Bernhard J Connemann; Carlos Schönfeldt-Lecuona
Journal:  Brain Sci       Date:  2019-11-13

8.  Alterations in Excitatory and Inhibitory Synaptic Development Within the Mesolimbic Dopamine Pathway in a Mouse Model of Prenatal Drug Exposure.

Authors:  Taylor Boggess; James C Williamson; Ethan B Niebergall; Hannah Sexton; Anna Mazur; Richard D Egleton; Lawrence M Grover; W Christopher Risher
Journal:  Front Pediatr       Date:  2021-12-13       Impact factor: 3.418

9.  Descriptions of Gabapentin Misuse and Associated Behaviors among a Sample of Opioid (Mis)users in South Florida.

Authors:  Mance E Buttram; Steven P Kurtz
Journal:  J Psychoactive Drugs       Date:  2020-08-04

10.  Electroacupuncture prevents cocaine-induced conditioned place preference reinstatement and attenuates ΔFosB and GluR2 expression.

Authors:  Ai T M Nguyen; Tran V B Quach; Peddanna Kotha; Szu-Yu Chien; Iona J MacDonald; Hsien-Yuan Lane; Cheng-Hao Tu; Jaung-Geng Lin; Yi-Hung Chen
Journal:  Sci Rep       Date:  2021-07-01       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.